Are depot antipsychotics ever self-tapering? Exploring the discontinuation of long-acting injectable psychosis drugs and those with delayed onset through in silico modelling

Clicks: 16
ID: 328419
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #14 of 21 articles by views in Schizophrenia Bulletin Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
ABSTRACT Background and Hypothesis Reducing and stopping antipsychotic medications can have longer-term positive outcomes for some patients. Despite common wisdom, abrupt discontinuation of several long-acting injectable (LAI) antipsychotic drugs results in rapid D2 occupancy reductions. We explored if abrupt discontinuation of LAI antipsychotics with slow clearance remained within specified constraints on rate of D2 occupancy change (RODOC), which might reduce risk of emerging symptoms of psychosis related to withdrawal or relapse. Study Design Pharmacokinetic data were collated for six LAI antipsychotic forms (aripiprazole lauroxil, olanzapine pamoate, paliperidone palmitate 1-, 3-, and 6-monthly, and risperidone microspheres). 52 studies comprising 6146 patients were included. In silico modelling was completed to predict RODOC from abrupt discontinuation. We used RODOC thresholds of five percentage point (pp) difference per month as a proxy measure to theoretically estimate the likelihood of withdrawal effects emerging, with sensitivity analyses for 2.5 and 10 pp/month. Study Results Abrupt cessation of LAIs is likely to exceed 5pp/month RODOC for all examined LAIs except paliperidone palmitate 6-monthly. Peak rates of D2 occupancy change per month for an average person ranged from 5pp/month (paliperidone palmitate 6-monthly) to 66.1pp/month (risperidone microspheres). Significant interpersonal variation in pharmacokinetic factors was observed. Conclusions Almost all LAI antipsychotic medications could theoretically cause withdrawal effects in most patients if abruptly discontinued without oral supplementation. However, abrupt discontinuation of longer-acting paliperidone palmitate could theoretically be successful for some patients. Prescribers must collaborate with patients when devising tapering regimens to ensure schedules are personalised and responsive to individual experience.
Reference Key
openalex_W7212352482 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors James R. O’Neill, Samantha L. McLean, David M Taylor, Mark A Horowitz
Journal Schizophrenia Bulletin Open
Year 2026
DOI
10.1093/schizbullopen/sgag037
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.